1. Abstract
The effort to develop vaccines based on economically accessible technological platforms available by developing countries vaccine manufacturers is essential to extend the immunization to the whole world population and to achieve the desired herd immunity, necessary to end the COVID-19 pandemic. Here we report on the development of a SARS-CoV-2 receptor-binding domain (RBD) protein, expressed in yeast Pichia pastoris. The RBD was modified with addition of flexible N- and C-terminal amino acid extensions aimed to modulate the protein/protein interactions and facilitate protein purification. Fermentation with yeast extract culture medium yielded 30–40 mg/L. After purification by immobilized metal ion affinity chromatography and hydrophobic interaction chromatography, the RBD protein was characterized by mass-spectrometry, circular dichroism, and binding affinity to angiotensin-converting enzyme 2 (ACE2) receptor. The recombinant protein shows high antigenicity with convalescent human sera and also with sera from individuals vaccinated with the Pfizer-BioNTech mRNA or Sputnik V adenoviral-based vaccines. The RBD protein stimulates IFNγ, IL-2, IL-6, IL-4, and TNFα in mice secreting splenocytes from PBMC and lung CD3+ enriched cells. Immunogenicity studies with 50 µg of the recombinant RBD formulated with alum, induce high levels of binding antibodies in mice and non-human primates, assessed by ELISA plates covered with RBD protein expressed in HEK293T cells. The mouse sera inhibited the RBD binding to ACE2 receptor in an in-vitro test and show neutralization of SARS-CoV-2 infection of Vero E6 cells. These data suggest that the RBD recombinant protein expressed in yeast P. pastoris is suitable as a vaccine candidate against COVID-19.
Highlights
The RBD protein (C-RBD-H6 PP) is expressed with high purity in P. pastoris.
Physico-chemical characterization confirms the right folding of the protein.
The recombinant protein shows high antigenicity with sera from convalescents.
The sera from animals inhibit the RBD-ACE2 binding and neutralize the virus.
The C-RBD-H6 protein stimulates IFNγ, IL-2, IL-6, IL-4, and TNFα in mice.
Competing Interest Statement
MLF, MBR, AMMD, DGR, ACR, GCS, GMP, EPV, MAA and GGN are co-authors of the Center for Genetic Engineering and Biotechnology patent application comprising the C-RBD-H6 PP protein as a vaccine antigen against SASR-CoV-2. All authors approved integrally the final article.
Funding Statement
This work was supported with funds from the BioCubaFarma, the Center for Genetic Engineering and Biotechnology, and by the Grant of the National Science and Technology Program - Biotechnology, Pharmaceutical Industry and Medical Technologies, of the Ministry of Science and Technology, project code PN385LH007-048. The Civilian Defense Scientific Research Center supported the microneutralization assays.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Center for Genetic Engineering and Biotechnology Institutional Ethical Committee approved the Informed Consent requested to human volunteers for the serum samples used. The animal studies Ethical Committee on Animal Experimentation of the Center for Genetic Engineering and Biotechnology (CIGB, Havana, Cuba) and the Center for Production of Laboratory Animals (CENPALAB, Bejucal, Cuba)approved the animal experiments.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All relevant data are included in the manuscript or can be accessible upon request.
Abbreviations
- RBD
- Receptor-binding domain
- COVID-19
- coronavirus disease 2019
- SARS-CoV-2
- severe acute respiratory syndrome coronavirus 2
- ACE2
- angiotensin-converting enzyme 2
- PBMC
- peripheral blood mononuclear cells
- IL-2
- Interleukin 2
- IL-4
- Interleukin 4
- IL-6
- Interleukin 6
- TNFα
- tumor necrosis factor-alpha
- IFNγ
- interferon gamma
- NHP
- non-human primates
- CHO
- Chinese hamster ovary cells
- BHK21
- baby hamster kidney cells
- HEK293T
- human embryonic kidney cells
- IMAC
- immobilized metal ion affinity chromatography
- RP
- reversed-phase chromatography
- CD
- circular dichroism
- OD
- optical density
- VNT
- viral neutralization titer
